22.87
0.37 (1.64%)
| Penutupan Terdahulu | 22.50 |
| Buka | 22.65 |
| Jumlah Dagangan | 270,662 |
| Purata Dagangan (3B) | 258,111 |
| Modal Pasaran | 1,117,409,920 |
| Harga / Buku (P/B) | 3.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2025 - 17 Mar 2025 |
| EPS Cair (TTM) | -1.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 17.44 |
| Aliran Tunai Operasi (OCF TTM) | -72.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -31.10 M |
| Pulangan Atas Aset (ROA TTM) | -21.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Enliven Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.39% |
| % Dimiliki oleh Institusi | 98.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2024 | 4,026,331 |
| Fairmount Funds Management Llc | 30 Sep 2024 | 3,202,798 |
| 5Am Venture Management, Llc | 30 Sep 2024 | 1,752,174 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 42.00 (BTIG, 83.65%) | Beli |
| Median | 38.50 (68.34%) | |
| Rendah | 36.00 (Jones Trading, 57.41%) | Beli |
| Purata | 38.75 (69.44%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 25.35 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 13 Dec 2024 | 42.00 (83.65%) | Beli | 23.15 |
| Baird | 15 Nov 2024 | 40.00 (74.90%) | Beli | 24.41 |
| Jones Trading | 31 Oct 2024 | 36.00 (57.41%) | Beli | 27.85 |
| HC Wainwright & Co. | 01 Oct 2024 | 37.00 (61.78%) | Beli | 26.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2024 | Pengumuman | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update |
| 07 Nov 2024 | Pengumuman | Enliven Therapeutics to Present at the Jefferies London Healthcare Conference |
| 28 Sep 2024 | Pengumuman | Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |